Recruiting
Phase 3

Aspirin & Heparin

Sponsor:

University of Calgary

Code:

NCT06494878

Conditions

Venous Thromboembolism

Postpartum Period

Aspirin

Low Molecular Weight Heparin

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Aspirin

Low-molecular-weight heparin

Study Details

Brief summary:

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Conditions

Venous Thromboembolism

Postpartum Period

Aspirin

Low Molecular Weight Heparin

Study ID

NCT06494878

Start date

Jun 4, 2026

Status verified date

Jun, 2026

Completion date

Dec, 2030

Anticipated

Primary completion date

Sep, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • ONE (or more) First Order Criterion:

1. Known inherited thrombophilia diagnosed prior to enrolment, regardless of family history of VTE:

i. Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S deficiency, and/or
2. Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND/OR

TWO (or more) Second Order Criteria:

1. Pre-pregnancy BMI ≥30 kg/m²
2. Smoking in the current pregnancy or within 3 months prior to pregnancy
3. Previous clinical history of superficial vein thrombosis
4. Preeclampsia
5. Current pregnancy ending in stillbirth (pregnancy loss >20 weeks gestation)
6. Unplanned cesarean delivery (unplanned = not a scheduled cesarean delivery)
7. Small-for-gestational-age infant at time of delivery (<3rd percentile adjusted for gestational age and sex)
8. Peripartum or postpartum infection (symptoms/signs of infection and documented fever and laboratory evidence of infection with positive blood cultures or an elevated white blood cell count based on local laboratory cutoffs)
9. Postpartum hemorrhage (≥1000 mL of blood loss, regardless of delivery mode)

Exclusion Criteria:

1. More than 48 hours since delivery at the time of randomization
2. Received more than 1 dose of LMWH since delivery
3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by their physician and/or local investigator. May include but is not limited to:

1. Documented history of provoked or unprovoked VTE
2. Mechanical heart valve(s)
3. Known antiphospholipid syndrome (APS)
4. Known high-risk inherited thrombophilia i) Antithrombin deficiency, or ii) Homozygous factor V Leiden, or iii) Homozygous prothrombin gene mutation, or iv) More than 1 thrombophilia: any combination of 2 or more: factor V Leiden, prothrombin gene mutation, protein C deficiency, protein S deficiency
4. Need for postpartum ASA as judged by their physician and/or local investigator. May include but is not limited to:

1. Documented history of myocardial infarction
2. Documented history of ischemic stroke or transient ischemic attack (TIA)
5. Active bleeding, excluding normal vaginal bleeding, at the time of randomization
6. Known medical condition as judged by their physician and/or local investigator to be a contraindication to ASA or LMWH including known ASA or LMWH allergy
7. <18 years of age
8. Unable or declined consent

Study Design

Enrollment

8805 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Aspirin

Low-dose aspirin (75-100 mg) once daily for 6 weeks.

active comparator: Low-molecular-weight heparin

Site-specific low-molecular-weight heparin regimen as prescribed by the treating physician.

Interventions

Aspirin

75-100 mg taken once daily by mouth.

Low-molecular-weight heparin

Low-molecular-weight heparin injections daily as prescribed by the treating physician.

Primary outcome measure

  • Symptomatic VTE [ Time Frame: 6 weeks ]

Central Contacts and Locations

Central contacts

Locations

Foothills Medical Centre

Recruiting

Calgary, Alberta, Canada, T2N 2T9

Contacts

More Information

Sponsor

University of Calgary

Last update posted

Jul 27, 2026

Last verified

Jun, 2026

Keywords

  • deep vein thrombosis
  • pulmonary embolism
  • postpartum
  • pregnancy
  • thrombophilia
  • cesarean delivery
  • preeclampsia
  • small-for-gestational age infant
  • postpartum hemorrhage
  • postpartum infection

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Calgary on 2026-07-27.